ABBOTT LABORATORIES Income (Loss) from Continuing Operations, Per Diluted Share
ABBOTT LABORATORIES (ABT) reported Income (Loss) from Continuing Operations, Per Diluted Share of $3.91 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2023-02-17
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for the quarter ending 2021-09-30 was $1.17, a 69.57% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for the quarter ending 2021-06-30 was $0.66, a 120.00% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for the quarter ending 2021-03-31 was $1.00, a 233.33% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for the quarter ending 2020-09-30 was $0.69, a 30.19% increase year-over-year.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for fiscal 2022 was $3.91, a 0.76% decline from fiscal 2021.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for fiscal 2021 was $3.94, a 58.23% increase from fiscal 2020.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for fiscal 2020 was $2.49, a 20.87% increase from fiscal 2019.
- ABBOTT LABORATORIES income (loss) from continuing operations, per diluted share for fiscal 2019 was $2.06, a 57.25% increase from fiscal 2018.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month | Income (Loss) from Continuing Operations, Per Diluted Share 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $3.91 10-K · filed 2023-02-17 | |||||||
| 2021-12-31 | $3.94 10-K · filed 2023-02-17 | |||||||
| 2021-09-30 | $1.17 10-Q · filed 2021-11-03 | $2.83 10-Q · filed 2021-11-03 | ||||||
| 2021-06-30 | $0.66 10-Q · filed 2021-08-04 | $1.66 10-Q · filed 2021-08-04 | ||||||
| 2021-03-31 | $1.00 10-Q · filed 2021-05-05 | |||||||
| 2020-12-31 | $2.49 10-K · filed 2023-02-17 | |||||||
| 2020-09-30 | $0.69 10-Q · filed 2021-11-03 | $1.29 10-Q · filed 2021-11-03 | ||||||
| 2020-06-30 | $0.30 10-Q · filed 2021-08-04 | $0.60 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | $0.30 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | $0.59 10-K · filed 2020-02-21 | $2.06 10-K · filed 2022-02-18 | ||||||
| 2019-09-30 | $0.53 10-Q · filed 2020-11-04 | $1.47 10-Q · filed 2020-11-04 | ||||||
| 2019-06-30 | $0.56 10-Q · filed 2020-07-29 | $0.94 10-Q · filed 2020-07-29 | ||||||
| 2019-03-31 | $0.38 10-Q · filed 2020-04-29 | |||||||
| 2018-12-31 | $0.37 10-K · filed 2020-02-21 | $1.31 10-K · filed 2021-02-19 | ||||||
| 2018-09-30 | $0.31 10-K · filed 2020-02-21 | $0.94 10-Q · filed 2019-10-31 | ||||||
| 2018-06-30 | $0.40 10-K · filed 2020-02-21 | $0.63 10-Q · filed 2019-07-31 | ||||||
| 2018-03-31 | $0.23 10-K · filed 2020-02-21 | |||||||
| 2017-12-31 | -$0.50 10-K · filed 2019-02-22 | $0.20 10-K · filed 2020-02-21 | ||||||
| 2017-09-30 | $0.32 10-K · filed 2019-02-22 | $0.69 10-Q · filed 2018-10-31 | ||||||
| 2017-06-30 | $0.15 10-K · filed 2019-02-22 | $0.37 10-Q · filed 2018-08-01 | ||||||
| 2017-03-31 | $0.22 10-K · filed 2019-02-22 | |||||||
| 2016-12-31 | $0.51 10-K · filed 2018-02-16 | $0.71 10-K · filed 2019-02-22 | ||||||
| 2016-09-30 | -$0.24 10-K · filed 2018-02-16 | $0.20 10-Q · filed 2017-11-02 | ||||||
| 2016-06-30 | $0.40 10-K · filed 2018-02-16 | $0.44 10-Q · filed 2017-08-02 | ||||||
| 2016-03-31 | $0.04 10-K · filed 2018-02-16 | |||||||
| 2015-12-31 | $0.46 10-K · filed 2017-02-17 | $1.72 10-K · filed 2018-02-16 | ||||||
| 2015-09-30 | $0.39 10-K · filed 2017-02-17 | $1.26 10-Q · filed 2016-11-03 | ||||||
| 2015-06-30 | $0.52 10-K · filed 2017-02-17 | $0.87 10-Q · filed 2016-08-03 | ||||||
| 2015-03-31 | $0.35 10-K · filed 2017-02-17 | |||||||
| 2014-12-31 | $0.41 10-K · filed 2016-02-19 | $1.12 10-K · filed 2017-02-17 | ||||||
| 2014-09-30 | $0.29 10-K · filed 2016-02-19 | $0.71 10-Q · filed 2015-11-05 | ||||||
| 2014-06-30 | $0.28 10-K · filed 2016-02-19 | $0.30 10-Q · filed 2014-08-05 | $0.42 10-Q · filed 2015-08-04 | $0.52 10-Q · filed 2014-08-05 | ||||
| 2014-03-31 | $0.14 10-K · filed 2016-02-19 | $0.22 10-Q · filed 2014-05-07 | ||||||
| 2013-12-31 | $0.31 10-K · filed 2015-02-27 | $0.37 10-K · filed 2014-02-21 | $1.26 10-K · filed 2016-02-19 | $1.50 10-K · filed 2014-02-21 | ||||
| 2013-09-30 | $0.41 10-K · filed 2015-02-27 | $0.49 10-Q · filed 2013-11-07 | $0.95 10-Q · filed 2014-11-06 | $1.13 10-Q · filed 2013-11-07 | ||||
| 2013-06-30 | $0.25 10-K · filed 2015-02-27 | $0.30 10-Q · filed 2013-08-06 | $0.64 10-Q · filed 2014-08-05 | |||||
| 2013-03-31 | $0.29 10-K · filed 2015-02-27 | $0.34 10-Q · filed 2013-05-08 | ||||||
| 2012-12-31 | -$0.33 10-K · filed 2014-02-21 | $0.15 10-K · filed 2015-02-27 | $0.36 10-K · filed 2014-02-21 | |||||
| 2012-09-30 | $0.21 10-K · filed 2014-02-21 | $0.69 10-Q · filed 2013-11-07 | ||||||
| 2012-06-30 | $0.26 10-K · filed 2014-02-21 | $0.47 10-Q · filed 2013-08-06 | ||||||
| 2012-03-31 | $0.22 10-K · filed 2014-02-21 | |||||||
| 2011-12-31 | $0.72 10-K · filed 2014-02-21 | |||||||
| 2010-12-31 | $2.96 10-K · filed 2011-02-18 | |||||||
| 2009-12-31 | $3.69 10-K · filed 2011-02-18 | |||||||
| 2008-12-31 | $3.03 10-K · filed 2011-02-18 | |||||||
| 2007-12-31 | $2.31 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |